<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139033</url>
  </required_header>
  <id_info>
    <org_study_id>13-110-0008</org_study_id>
    <nct_id>NCT02139033</nct_id>
  </id_info>
  <brief_title>A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome</brief_title>
  <official_title>A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocusoft, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ocusoft, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs&#xD;
      and symptoms of dry eye syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Film Break-Up Time</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular surface damage as measured by fluorescein staining</measure>
    <time_frame>Day 15</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retain 1-2 drops, bilaterally, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retaine™</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age;&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Have a reported history of dry eye;&#xD;
&#xD;
          -  Have a history of use or desire to use eye drops;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any clinically significant eye findings that require therapeutic treatment,&#xD;
             and/or in the opinion of the investigator may interfere with study parameters;&#xD;
&#xD;
          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses&#xD;
             during the study;&#xD;
&#xD;
          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the&#xD;
             last 12 months;&#xD;
&#xD;
          -  Have used Restasis® within 30 days of Visit 1;&#xD;
&#xD;
          -  Be a woman who is pregnant, nursing or planning a pregnancy;&#xD;
&#xD;
          -  Be unwilling to submit a urine pregnancy test if of childbearing potential;&#xD;
&#xD;
          -  Have a known allergy and/or sensitivity to the test article or its components;&#xD;
&#xD;
          -  Have a condition or be in a situation which the investigator feels may put the subject&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study;&#xD;
&#xD;
          -  Be currently enrolled in an investigational drug or device study or have used an&#xD;
             investigational drug or device within 30 days of Visit 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye, Dry Eye Syndrome, Retaine, KCS, Keratoconjunctivitis sicca</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

